6533b837fe1ef96bd12a2828

RESEARCH PRODUCT

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia – a study of the Acute Leukemia Working Party of the EBMT

Emmanuelle PolgeDonald BunjesMatthias StelljesEva WagnerPeter DregerUwe PlatzbeckerNicolaus KrögerThomas HeinickeBipin N. SavaniArnold GanserMyriam LabopinDietrich W. BeelenArnon NaglerJohanna TischerMohamad MohtyChristof ScheidWolfgang BethgeArne Brecht

subject

OncologyCancer Researchmedicine.medical_specialtyTransplantation ConditioningMedizinGraft vs Host Disease03 medical and health sciencesMyelogenous0302 clinical medicineRefractoryhemic and lymphatic diseasesInternal medicinemedicineHumansIn patientBusulfanAgedRetrospective StudiesAcute leukemiabusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseTransplantationLeukemia Myeloid AcuteLeukemiaOncology030220 oncology & carcinogenesisRelapsed refractoryStem cellbusiness030215 immunology

description

The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability.

yearjournalcountryeditionlanguage
2020-10-11Leukemia & Lymphoma
https://doi.org/10.1080/10428194.2020.1827248